Cardiol Therapeutics Inc. (CRDL) stock
Close on Nov 20, 2026Market cap $86.48MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Dec 31, 2025
Valuation
- Market cap
- C$123.29M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -19.37%
Fundamentals
- EPS, diluted
- -0.39 CAD
- Free cash flow
- -C$23.88M
Trading
- Previous close
- $0.88
- Open
- $0.88
- Day's range
- $0.84 – $0.90
- Volume
- 552,966
- Average volume (20 days)
- 523,945
- Beta (5 years)
- 1.19
- RSI (14 days)
- 25.6
- Volatility (1 year)
- 62.3%
- Relative volume
- 0.46×
- WACC
- 11.0%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 20, 2026. The S&P 500 is measured by the SPY fund.
| Period | CRDL | S&P 500 | Difference | CRDL per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -25.0% | -10.3% | −14.7 pts | ||
| 3 months | -54.2% | -9.3% | −44.9 pts | ||
| Year to date | -9.6% | +1.9% | −11.5 pts | ||
| 1 year | -10.6% | +6.9% | −17.5 pts | ||
| 3 years | +0.2% | +57.5% | −57.3 pts | +0.1% | +16.3% |
| 5 years | -57.9% | +57.3% | −115.2 pts | -15.9% | +9.5% |
Seven years at a glance
Fiscal years 2019 to 2025, CAD
Revenue
Operating income
EPS, diluted
Free cash flow
Press releases
Releases Cardiol Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Cardiol Therapeutics
Biological Products, (No Diagnostic Substances)
Cardiol Therapeutics Inc. is a Canadian life sciences company focused on the development of pharmaceutical therapies and therapeutic strategies. Its primary activities center on the research, preclinical evaluation, and clinical study of novel drug candidates designed to address inflammation, cardiac disorders, and related cardiovascular conditions. Rather than distributing mass-market consumer products or operating commercial retail segments, the entity concentrates its operations entirely on biotechnology and biopharmaceutical research programs aimed at clinical validation for patient populations suffering from heart diseases.
Company profile, executives and historyCardiol Therapeutics stock: common questions
What is Cardiol Therapeutics's stock price?
CRDL closed at $0.86 on Nov 20, 2026, down 2.28% on the day.
What is Cardiol Therapeutics's market cap?
Cardiol Therapeutics was worth $86.48M at the close on Nov 20, 2026: the share price times the diluted shares outstanding.
What is CRDL's P/E ratio?
Cardiol Therapeutics lost money over fiscal 2025 (diluted EPS -0.39 CAD), so it has no meaningful P/E ratio.
Does Cardiol Therapeutics pay a dividend?
No. Cardiol Therapeutics has not paid a cash dividend over the last twelve months.
How has CRDL stock performed over the past year?
Including dividends, CRDL returned -10.6% over the past year, against +6.9% for the S&P 500.
Who are Cardiol Therapeutics's competitors?
Companies most similar to Cardiol Therapeutics by business, industry and size include RLAY, CLDI, SLDB, PALI, ENGN.
See a number that looks wrong?